Overview Dividends

(INGN) Inogen - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US45780L1044

Portable Concentrators, Stationary Concentrators, Batteries, Accessories

INGN EPS (Earnings per Share)

EPS (Earnings per Share) of INGN over the last years for every Quarter: "2020-09": -0.08, "2020-12": -0.23, "2021-03": -0.03, "2021-06": 0.22, "2021-09": 0.53, "2021-12": -1.01, "2022-03": -0.62, "2022-06": -0.15, "2022-09": -0.42, "2022-12": -0.2, "2023-03": -0.88, "2023-06": -0.42, "2023-09": -0.55, "2023-12": -1.14, "2024-03": -0.62, "2024-06": -0.24, "2024-09": -0.25, "2024-12": -0.24, "2025-03": -0.11, "2025-06": -0.15, "2025-09": -0.02,
EPS Growth (3Y CAGR): 6.42%
EPS Trend (3Y Correlation): 59.7%

INGN Revenue

Revenue of INGN over the last years for every Quarter: 2020-09: 74.329, 2020-12: 73.978, 2021-03: 86.932, 2021-06: 101.563, 2021-09: 93.105, 2021-12: 76.403, 2022-03: 80.385, 2022-06: 103.376, 2022-09: 105.389, 2022-12: 88.091, 2023-03: 72.162, 2023-06: 83.635, 2023-09: 83.967, 2023-12: 75.896, 2024-03: 78.025, 2024-06: 88.765, 2024-09: 88.834, 2024-12: 80.081, 2025-03: 82.28, 2025-06: 92.277, 2025-09: 92.39,
Revenue Growth (3Y CAGR): 1.75%
Revenue Trend (3Y Correlation): 48.0%
Risk via 10d forecast
Volatility 68.5%
Value at Risk 5%th 93.2%
Relative Tail Risk -17.30%
Reward TTM
Sharpe Ratio -0.58
Alpha -47.32
Character TTM
Hurst Exponent 0.487
Beta 0.946
Beta Downside 0.604
Drawdowns 3y
Max DD 83.81%
Mean DD 62.28%
Median DD 67.60%

Description: INGN Inogen October 29, 2025

Inogen, Inc. (NASDAQ: INGN) designs, manufactures, and markets portable and stationary oxygen-concentrator systems for long-term oxygen therapy (LTOT) in the United States and abroad. Its product line includes the Inogen One and Inogen Rove ambulatory devices, the Rove 4 portable concentrator, the Inogen At Home stationary unit, the Simeox airway-clearance system, batteries, and accessories, with a rental-to-patient model that supplements direct sales.

Key operating metrics (2023 FY) show revenue of roughly $210 million, a net loss of $30 million, and cash and equivalents of $120 million, giving the company an estimated 12-month cash runway under current burn-rate assumptions. Growth drivers include the aging U.S. population (≈ 16 % over 65) and increasing outpatient LTOT utilization, while reimbursement pressure from Medicare and competition from larger OEMs such as Philips Respironics remain material risks. The broader health-care equipment sector is benefiting from a shift toward home-based care, which historically adds a 4-6 % premium to valuation multiples for companies with proven distribution networks.

For a deeper, data-driven valuation framework, you might explore the Inogen profile on ValueRay.

INGN Stock Overview

Market Cap in USD 187m
Sub-Industry Health Care Equipment
IPO / Inception 2014-02-14
Return 12m vs S&P 500 -39.5%
Analyst Rating 3.67 of 5

INGN Dividends

Currently no dividends paid

INGN Growth Ratios

CAGR 3y -33.18%
CAGR/Max DD Calmar Ratio -0.40
CAGR/Mean DD Pain Ratio -0.53
Current Volume 147.6k
Average Volume 160.2k

Piotroski VR‑10 (Strict, 0-10) 2.5

Net Income (-25.4m TTM) > 0 and > 6% of Revenue (6% = 20.8m TTM)
FCFTA -0.05 (>2.0%) and ΔFCFTA 0.04pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 39.99% (prev 36.24%; Δ 3.74pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.04 (>3.0%) and CFO -13.3m > Net Income -25.4m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 3.14 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (26.4m) change vs 12m ago 11.19% (target <= -2.0% for YES)
Gross Margin 46.38% (prev 44.22%; Δ 2.16pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 113.2% (prev 108.3%; Δ 4.91pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -10.73 (EBITDA TTM -8.08m / Interest Expense TTM -2.68m) >= 6 (WARN >= 3)

Altman Z'' -1.03

(A) 0.45 = (Total Current Assets 203.7m - Total Current Liabilities 64.9m) / Total Assets 307.0m
(B) -0.55 = Retained Earnings (Balance) -168.5m / Total Assets 307.0m
(C) -0.09 = EBIT TTM -28.8m / Avg Total Assets 306.6m
(D) -1.50 = Book Value of Equity -164.7m / Total Liabilities 109.8m
Total Rating: -1.03 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 32.83

1. Piotroski 2.50pt = -2.50
2. FCF Yield -17.88% = -5.0
3. FCF Margin -4.15% = -1.56
4. Debt/Equity 0.09 = 2.50
5. Debt/Ebitda 11.08 = -2.50
6. ROIC - WACC (= -24.07)% = -12.50
7. RoE -13.21% = -2.20
8. Rev. Trend 48.02% = 3.60
9. EPS Trend 59.71% = 2.99

What is the price of INGN shares?

As of November 15, 2025, the stock is trading at USD 6.90 with a total of 147,637 shares traded.
Over the past week, the price has changed by -1.29%, over one month by -17.56%, over three months by -10.04% and over the past year by -30.65%.

Is Inogen a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Inogen (NASDAQ:INGN) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 32.83 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of INGN is around 4.61 USD . This means that INGN is currently overvalued and has a potential downside of -33.19%.

Is INGN a buy, sell or hold?

Inogen has received a consensus analysts rating of 3.67. Therefor, it is recommend to hold INGN.
  • Strong Buy: 1
  • Buy: 1
  • Hold: 0
  • Sell: 1
  • Strong Sell: 0

What are the forecasts/targets for the INGN price?

Issuer Target Up/Down from current
Wallstreet Target Price 13 88.4%
Analysts Target Price 13 88.4%
ValueRay Target Price 5.2 -24.9%

INGN Fundamental Data Overview November 15, 2025

Market Cap USD = 186.8m (186.8m USD * 1.0 USD.USD)
P/S = 0.5382
P/B = 0.9487
P/EG = 3.48
Beta = 1.811
Revenue TTM = 347.0m USD
EBIT TTM = -28.8m USD
EBITDA TTM = -8.08m USD
Long Term Debt = 18.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.12m USD (from shortTermDebt, last quarter)
Debt = 18.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -89.5m USD (from netDebt column, last quarter)
Enterprise Value = 80.5m USD (186.8m + Debt 18.2m - CCE 124.5m)
Interest Coverage Ratio = -10.73 (Ebit TTM -28.8m / Interest Expense TTM -2.68m)
FCF Yield = -17.88% (FCF TTM -14.4m / Enterprise Value 80.5m)
FCF Margin = -4.15% (FCF TTM -14.4m / Revenue TTM 347.0m)
Net Margin = -7.31% (Net Income TTM -25.4m / Revenue TTM 347.0m)
Gross Margin = 46.38% ((Revenue TTM 347.0m - Cost of Revenue TTM 186.1m) / Revenue TTM)
Gross Margin QoQ = 50.82% (prev 44.80%)
Tobins Q-Ratio = 0.26 (Enterprise Value 80.5m / Total Assets 307.0m)
Interest Expense / Debt = 9.67% (Interest Expense 1.76m / Debt 18.2m)
Taxrate = 2.68% (-146.0k / -5.44m)
NOPAT = -28.0m (EBIT -28.8m * (1 - 2.68%)) [loss with tax shield]
Current Ratio = 3.14 (Total Current Assets 203.7m / Total Current Liabilities 64.9m)
Debt / Equity = 0.09 (Debt 18.2m / totalStockholderEquity, last quarter 197.2m)
Debt / EBITDA = 11.08 (negative EBITDA) (Net Debt -89.5m / EBITDA -8.08m)
Debt / FCF = 6.22 (negative FCF - burning cash) (Net Debt -89.5m / FCF TTM -14.4m)
Total Stockholder Equity = 192.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -8.27% (Net Income -25.4m / Total Assets 307.0m)
RoE = -13.21% (Net Income TTM -25.4m / Total Stockholder Equity 192.1m)
RoCE = -13.69% (EBIT -28.8m / Capital Employed (Equity 192.1m + L.T.Debt 18.2m))
RoIC = -14.58% (negative operating profit) (NOPAT -28.0m / Invested Capital 192.1m)
WACC = 9.49% (E(186.8m)/V(205.0m) * Re(9.50%) + D(18.2m)/V(205.0m) * Rd(9.67%) * (1-Tc(0.03)))
Discount Rate = 9.50% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.43%
Fair Price DCF = unknown (Cash Flow -14.4m)
EPS Correlation: 59.71 | EPS CAGR: 6.42% | SUE: 0.73 | # QB: 0
Revenue Correlation: 48.02 | Revenue CAGR: 1.75% | SUE: 0.07 | # QB: 0

Additional Sources for INGN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle